share_log

三葉草生物-B:股東週年大會通告

CLOVER BIO-B: Notice of Annual General Meeting

Hong Kong Stock Exchange ·  Apr 25 07:16
Summary by Moomoo AI
三葉草生物製藥有限公司將於2024年6月20日舉行股東週年大會,地點為中國(四川)自由貿易試驗區成都高新區。大會將審議多項普通決議案,包括採納截至2023年12月31日止年度的經審核綜合財務報表及相關報告,重選梁朋博士、吳曉濱博士和Jeffrey FARROW先生為董事,以及授權董事會釐定董事酬金。此外,將續聘安永會計師事務所為核數師並授權董事會釐定其酬金。大會還將考慮授權董事在特定期間內配發新股份或購股權,並購回不超過已發行股本總面值10%的公司股份。特別決議案包括批准修訂公司組織章程大綱及章程細則。股東將於2024年6月14日至20日間無法辦理股份過戶登記,以符合出席大會的資格。
三葉草生物製藥有限公司將於2024年6月20日舉行股東週年大會,地點為中國(四川)自由貿易試驗區成都高新區。大會將審議多項普通決議案,包括採納截至2023年12月31日止年度的經審核綜合財務報表及相關報告,重選梁朋博士、吳曉濱博士和Jeffrey FARROW先生為董事,以及授權董事會釐定董事酬金。此外,將續聘安永會計師事務所為核數師並授權董事會釐定其酬金。大會還將考慮授權董事在特定期間內配發新股份或購股權,並購回不超過已發行股本總面值10%的公司股份。特別決議案包括批准修訂公司組織章程大綱及章程細則。股東將於2024年6月14日至20日間無法辦理股份過戶登記,以符合出席大會的資格。
Clover Biopharmaceuticals Co., Ltd. will hold its Annual General Meeting on June 20, 2024. The venue will be located in Chengdu High New Zone, China (Sichuan) Pilot Free Trade Zone. The General Meeting will consider a number of ordinary resolutions, including the adoption of the audited consolidated financial statements and related reports for the year ended December 31, 2023, the re-election of Dr. Leung Pan, Dr. Wu Xiaobin and Mr. Jeffrey FARROW as directors, and authorizing the Board to determine the remuneration of directors. In addition, EY will be reappointed as auditor and authorized by the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing directors to issue new shares or share options within a specified period and...Show More
Clover Biopharmaceuticals Co., Ltd. will hold its Annual General Meeting on June 20, 2024. The venue will be located in Chengdu High New Zone, China (Sichuan) Pilot Free Trade Zone. The General Meeting will consider a number of ordinary resolutions, including the adoption of the audited consolidated financial statements and related reports for the year ended December 31, 2023, the re-election of Dr. Leung Pan, Dr. Wu Xiaobin and Mr. Jeffrey FARROW as directors, and authorizing the Board to determine the remuneration of directors. In addition, EY will be reappointed as auditor and authorized by the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing directors to issue new shares or share options within a specified period and to repurchase company shares not exceeding 10% of the total issued share capital. The special resolution included the approval of amendments to the Company's Articles of Association and the Articles of Association. Shareholders will not be able to register shares from 14 to 20 June 2024 in order to be eligible to attend the General Meeting.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more